Year-to-Date Metrics and Trends for the Gene Therapy, Cell Therapy, Tissue Engineering,and Broader Regenerative Medicine Sector.

ARM today released its most recent quarterly sector report, offering an in-depth look at the gene therapy, cell therapy, tissue engineering, and broader global regenerative medicine sector trends and metrics in the second quarter and first half of 2019. 
By further curating information provided by ARM’s data partner Informa, the quarterly data report details industry-specific statistics compiled from 932 gene therapy, cell therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events, and ARM’s current strategic priorities.

Key findings include:

• Globally, companies active in gene and cell therapies and other regenerative medicines raised $4.8 billion in the first half of 2019,including $2.6 billion in Q2. The report also includes financial data broken out by technology type and financing type.
• There were 1,069 clinical trials underway worldwide at the close of the second quarter of 2019, with more than 60% of those in oncology and 6% in cardiovascular disorders. The report also includes figures on clinical trials by phase and indication, as well as by technology type.
• In Europe and Israel, 234 therapeutic developers have raised $1.3B (€1.2B) year-to-date, a 17% increase year-over-year from H1 2018. There are currently 266 clinical trials underway sponsored by companies headquartered in Europe.
• Two gene therapies were approved in Q2 2019: the FDA approved AveXis / Novartis’s Zolgensma for the treatment of spinal muscular atrophy, and in Europe, bluebird bio’s Zynteglo was approved for transfusion-dependent beta thalassemia. As of the end of Q2, there were 562 gene therapy clinical trials ongoing for rare diseases worldwide, and $3.1 billion has been raised to develop these therapies YTD.